Conversely, the use of bendamustine as first therapy line (first therapy line vs. third line or more OR = 0.28, p = 0.022), baseline hemoglobin level > 10 g/dL (Hb > 10 g/dL vs. ≤10 g/dL OR = 0.41, p = 0.029), initial platelets count > 100,000/μL (plts > 100,000/μL vs. plts ≤ 100,000/μL OR = 0.37, p = 0.029), and trimethoprim-sulfamethoxazole prophylaxis (prophylaxis vs. no prophylaxis: OR = 0.43, p = 0.036) correlated with lower occurrence of infections. This evidence concerns the gene GSTM1 and infection.